What are the potential implications for the company's capital structure and future financing needs?

Capital‑structure impact – By extending the expiration of the 650 000 warrants, DIAGNOS gives investors an extra ~6 months to decide whether to convert the warrants into common equity. If a significant portion is exercised, the company will raise additional cash without adding debt, improving its balance‑sheet liquidity and reducing reliance on future debt financings. However, each exercised warrant will increase the share count, diluting existing shareholders and lowering earnings‑per‑share and any current valuation multiples. The longer window also means the market will continue to price in a “potential‑dilution” risk, which can keep the stock’s beta slightly elevated and suppress short‑term price appreciation.

Financing needs & trading outlook – The extension signals that DIAGNOS may not be urgently seeking fresh capital through a traditional equity offering, perhaps because its cash runway remains adequate or it prefers to avoid a downround. Nonetheless, the firm is likely to rely on the warrant proceeds as a key source of funding for R&D, AI platform scaling, or regulatory milestones. Traders should watch the warrant‑exercise window (Sept 2025 → Mar 2026) for spikes in volume or price moves that often precede large‑scale conversions. A buildup in open‑interest on the warrants or a rise in the underlying stock’s implied volatility could indicate that investors expect the warrants to be exercised, which would be a bullish signal for liquidity but a bearish one for dilution‑adjusted valuation. In the near term, maintaining a neutral‑to‑slightly‑bullish stance is prudent: buy on pull‑backs if the stock trades below its 20‑day moving average with solid volume, but be prepared to trim if the price approaches levels where the market fully prices in the dilution risk (e.g., a 10‑15 % drop from recent highs).